Bridging the Gap Between Innovation and Capital
AbbieVie Ventures
Focus on therapeutic companies
Program
Calling all early-stage biotech and novel therapeutics companies!
AbbVie Ventures is the strategic venture arm of AbbVie, with the mission to invest in transformational scientific opportunities that align to core AbbVie R&D interests. The team strives to access next-generation science and build relationships with emerging scientific leaders aiming to deliver innovative medicines and enhance patient lives.
Investing since 2009, AbbVie Ventures focuses exclusively on novel, transformational therapeutics at discovery and preclinical stages. Aligning with AbbVie’s strategic focus, their investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics.
The current AbbVie Venture portfolio is comprised of over 20 companies based in the US and Europe, where the team seeks approximately 6-8 new investments annually, as either syndicate lead or co-lead. The ideal investment stage is Seed or Series A, and the team also has the capability to consider new company creation opportunities.
Event
LaunchBio and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with AbbieVie Ventures.
Applications will be selected based on meeting the following criteria:
Geography:
Not restricted.
Company type:
Early-stage life science, biotech, and therapeutics companies across multiple drug modalities.
Areas of Interest:
- Immunology
- Oncology
- Neuroscience
- Eye Care
- Aesthetics
-
- Small Molecules
- Monoclonal/Multispecific Antibodies
- ADCs
- Target protein degradation
- Gene Therapy
- In-vivo Cell Therapies
Stage:
Companies seeking Pre-Seed, Seed and Series A.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Silicon Valley Bank, a division of First Citizens Bank.